Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both Medications
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
Dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagonlike peptide-1 (GLP-1) mimetics or
analogs, which rely on the gastrointestinal hormones that are part of the incretin system for
the treatment of T2DM, provide a therapeutic alternative to common oral antihyperglycemic
agents (eg, sulfonylureas, thiazolidinediones). Although GLP-1 analogs and DPP-4 inhibitor
medications are effective, there are differences between these products, including method of
administration (injectable versus oral). Previous studies have shown that patients prefer
additional oral agents over injectable agents because of fear of injections and the desire to
avoid them. Patient preference is both clinically and financially important, as it can have
long-term implications in terms of patients' motivation and insight into their disease state
and its treatment, which might have a direct impact on the patient's compliance and treatment
adherence. The aim of the current study is to evaluate the proportion of T2DM patients
preferring oral anti-diabetic treatment with vildagliptin + metformin versus an injectable
anti-diabetic treatment with liraglutide after 4 weeks of treatment with each medication.